University Medical Center Utrecht (UMCU)

24/11/2021
22/02/2024
Institution
Educational Institution
Hospital/Clinic/Other health care facility
Download as PDF
Institution identification

Institution ID

44417

Institution full name and acronym

University Medical Center Utrecht (UMCU)

Institution countries

Netherlands

Type of institution

Educational Institution
Hospital/Clinic/Other health care facility

Institution website

ENCePP partner

Yes
Institution description
The mission of the UMCU Clinical Pharmacy research program is to explain,predict and improve patients’ response to pharmacOtherapeutic treatment using pharmacoepidemiological and clinical pharmacological approaches. The research program finds its inspiration in needs and observations from daily patient care. Within this general scope,the research program focuses on three areas: children (patient group oriented),central nervous system drugs(exposure/drug group oriented),and drug induced illness (outcome oriented,i.e. side effects,toxicology,medication errors). The department of Clinical Pharmacy produces >40 peer reviewed publications per year in the area of pharmacoepidemiology,pharmacovigilence and clinical pharmacology.
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
No

Contact details

Studies conducted by the institution

Study protocol objective 2_feasibility assessement: Comparative effectiveness and safety studies using the target trial emulation and estimand frameworks (TARGET-EU-FA)
A non-interventional observational study assessing the safety and tolerability of ACARIZAX® in adults (18-65 years of age) (RELIEF)
A Post-Authorisation Safety Study (PASS) of ABRYSVO (Respiratory Syncytial Virus Stabilised Prefusion Subunit Vaccine) in Pregnant Women and their Offspring in a Real World Setting in Europe and UK (C3671026)
A post-authorisation safety study of ABRYSVO in immunocompromised, or renally or hepatically impaired adults aged 60 years and older in a real world setting in Europe and UK (C3671038)
A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources (COVID-19)
A Real World Evidence prospective cohort study in the management of metastatic colorectal cancer: a clinical and patient perspective (PROMETCO)
ACCESS template protocol for safety of COVID-19 vaccines
ACCESS template protocols for effectiveness of COVID-19 vaccines (ACCESS-effectiveness)
ADEPT: feasibility of estimating the risk of adverse pregnancy, neonatal and child outcomes following either in utero ASM exposure through the mother, or peri-conceptional ASM exposure through the father
ADEPT: The utilisation of antiseizure medications in pregnant women, other women of childbearing potential, and men: a multi-database study from 7 European countries
Alofisel-5003: An Observational Post-Marketing Study on the Effectiveness and Safety of Darvadstrocel in Patients With Crohn's Disease and Complex Perianal Fistulas (INSPIRE)
An Observational Post-Authorization Safety Study to Assess the Safety of Ad26.COV2.S Using European Healthcare Data through VAC4EU (COVID-19)
Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines (ACCESS-BGR)
Clinical features of COVID-19 in Pediatric Patients (COPP-study)
Cohort Event Monitoring of safety of COVID-19 vaccines in special populations (pregnant and lactating women, children and adolescents, immunocompromised, people with history of allergy, people with prior SARS-CoV-2 infection) (Covid-Vaccine-Monitor CVM)
Cohort monitoring of Adverse Events of Special Interest and COVID-19 diagnoses prior to and after COVID-19 vaccination (ECVM)
Comparative effectiveness and safety studies using the target trial emulation and estimand frameworks (TARGET-EU)
CONSIGN study: COVID-19 infection and medicines in pregnancy - a multinational registry based study
Coverage of COVID-19 vaccines in electronic healthcare databases: a protocol template from the ACCESS project
COVID-19 infections and medicines in pregnancy- the INOSS collaboration (INOSS CONSIGN)
Data characterization of population-based data sources: ConcePTION pipeline
Description of international collaboration in the area of medicines use and effects in COVID-19 affected pregnancies (CONSIGN-International, CONSIGN meta-analyses))
Effectiveness of heterologous and booster Covid-19 vaccination in 5 European countries, using a cohort approach in children and adults with a full primary Covid-19 vaccination regimen (Covid Vaccines Effectiveness (CoVE))
Exposure and coverage to routine schedule vaccines in different EU countries (ADVANCE-POC2)
Impact of EU label changes and revised pregnancy prevention programme for medicinal products containing valproate: utilisation and prescribing trends
Impact of EU label changes and revised pregnancy prevention programme for oral retinoid containing medicinal products: utilization and prescribing trends
Implementation of controlled access to and distribution of medicinal products in European Union (CONTROL-EU)
Implementation of EU risk minimisation measures for medicinal products in clinical guidelines
Intranasal Esketamine Against Depression. A real world clinical treatment Cohort-Study in the Netherlands (INESKAD)
Post Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
Post-Authorisation Active Surveillance Study of Myocarditis and Pericarditis Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
Post-Authorisation Safety Study of Comirnaty Original/Omicron BA.1 and Comirnaty Original/Omicron BA.4-5 in Europe
Rapid Safety Assessment of SARS-CoV-2 vaccines in EU Member States using electronic health care datasources (CVM Covid19-Vaccine-Monitor-EHR)
Safety of Paxlovid Among Patients with Moderate or Severe Hepatic or Renal Impairment
Safety of Paxlovid During Pregnancy
SAFETY-VAC: Background incidence estimation of flares of pre-existing chronic diseases using pan-European electronic healthcare data sources.
SAFETY-VAC: Network of Data Sources for Vaccine Safety Evaluation
SAFETY-VAC: Phenotype proposal and rates of immunocompromised populations in real-world data sources.
Strengthening Use of Real-World Data in Medicines Development: Metadata for Data Discoverability and Study Replicability (MINERVA)
Testing new approaches to monitoring benefit/risk with pertussis vaccines as test case: Incidence rates of pertussis and pertussis related outcomes of whole-cell pertussis and acellular pertussis vaccines in pre-school children (benefit study on pertussis vaccination)
VAC4EU Postauthorisation Effectiveness Study of BIMERVAX® Vaccine in Europe
VAC4EU Postauthorisation Safety Study of BIMERVAX® Vaccine in Europe